RE: Why has Sprinter not been stopped on efficacy grounds19 Nov 2021 11:26
Merck and the big boys have deeper pockets and can afford to gamble on going for an early approval.
For us, we need data. The full data set will show up the true value of SNG001. Stopping early could have us drowned out by the big boys marketing muscle and media profiles.
Full results, if as good as P2, will trump any banana skins thrown our way.